Analysts Offer Predictions for SCYNEXIS, Inc.'s FY2025 Earnings (NASDAQ:SCYX)

SCYNEXIS, Inc. (NASDAQ:SCYX - Free Report) - Research analysts at Brookline Capital Management upped their FY2025 earnings per share estimates for shares of SCYNEXIS in a research note issued to investors on Wednesday, May 8th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of $0.07 per share for the year, up from their prior estimate of $0.05. The consensus estimate for SCYNEXIS's current full-year earnings is ($0.08) per share. Brookline Capital Management also issued estimates for SCYNEXIS's FY2027 earnings at $0.25 EPS and FY2028 earnings at $0.09 EPS.

SCYNEXIS (NASDAQ:SCYX - Get Free Report) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.70). The company had revenue of $5.80 million during the quarter, compared to the consensus estimate of $26.14 million. SCYNEXIS had a net margin of 47.84% and a return on equity of 156.27%.

A number of other equities analysts have also recently issued reports on SCYX. StockNews.com cut shares of SCYNEXIS from a "buy" rating to a "hold" rating in a research report on Monday, March 18th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of SCYNEXIS in a research report on Monday, April 1st.

SCYNEXIS Trading Up 3.2 %

Shares of NASDAQ SCYX traded up $0.06 during mid-day trading on Friday, hitting $1.94. The stock had a trading volume of 366,092 shares, compared to its average volume of 162,733. The firm has a market cap of $73.29 million, a P/E ratio of 1.47 and a beta of 1.49. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.26 and a current ratio of 6.26. The business has a 50 day moving average price of $1.57 and a two-hundred day moving average price of $1.73. SCYNEXIS has a 1 year low of $1.35 and a 1 year high of $3.87.

Institutional Investors Weigh In On SCYNEXIS

Several institutional investors and hedge funds have recently modified their holdings of the stock. TFB Advisors LLC bought a new position in SCYNEXIS in the fourth quarter worth about $27,000. Park Avenue Securities LLC purchased a new position in shares of SCYNEXIS in the 3rd quarter valued at approximately $32,000. Simplicity Wealth LLC bought a new stake in shares of SCYNEXIS during the first quarter valued at approximately $29,000. O Shaughnessy Asset Management LLC bought a new stake in shares of SCYNEXIS during the third quarter valued at approximately $94,000. Finally, Chicago Partners Investment Group LLC raised its holdings in SCYNEXIS by 30.6% in the third quarter. Chicago Partners Investment Group LLC now owns 53,321 shares of the company's stock worth $122,000 after purchasing an additional 12,492 shares in the last quarter. 54.37% of the stock is owned by hedge funds and other institutional investors.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.